Moss, 30 November 2021

Reference is made to the annual general meeting 4 May 2021 where a statement of remuneration to key personnel was given. In accordance with this statement the board of Gentian Diagnostics ASA has allocated a total of 165,674 options to key employees under the existing option program.

The following number of options have been allocated to primary insiders of Gentian Diagnostics ASA:

Njaal Kind, Group Chief Financial Officer: 40,674 options. Following the allocations Mr. Kind hold 21,125 shares and 155,670 options in the Company.

Erling Sundrehagen, Chief Scientific Officer: 20,000 options. Following the allocation Mr. Sundrehagen and related parties hold 184,083 shares and 120,000 options in the Company.

Torsten Knüttel, Vice President R&D: 20,000 options. Following the allocation Mr. Knüttel hold 1,125 shares and 30,000 options in the Company.

Jack Andreassen, Vice President Business Development:  2,500 options. Following the allocation Mr. Andreassen hold 4,385 shares and 22,500 options in the Company.

Markus Jaquemar, Vice President Sales and Marketing: 2,500 options. Following the allocation Mr. Jaquemar holds 22,500 options in the Company. 

Attached is the notifications of the transactions pursuant to the market abuse regulation article 19. 

The exercise price for the options granted is NOK 72.60 being the average volume-weighted share price on the Oslo Stock Exchange for the past 10 trading days prior to 24 November. The right to exercise the options is vested over a period of 3 years, with 1/3 of the options vesting by the end of each year as follows: (i) 1/3 of the options granted, no earlier than 2 years after the allocation date (ii) 1/3 of the options granted, no earlier than 3 years after the allocation date (iii) 1/3 of the options granted, no earlier than 4 years after the allocation date. 

For further information, please contact:

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading Act.